AMLM25 : An ALLG Phase 2 study to Investigate Novel Triplets to Extend Remission with VENetoclax in Elderly (INTERVENE) Acute Myeloid Leukaemia

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

60+Age Over 60

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy | Blood / Myeloma / LymphomaAcute Myeloid Leukaemia

Trial Overview Read MoreRead more

This phase II trial is investigating different chemotherapy combinations for the treatment of elderly patients that have Acute Myeloid Leukaemia .
 

This trial is treating patients with acute myeloid leukaemia.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have been diagnosed with cancer, but have not received any treatment.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

An ALLG Phase 2 study to Investigate Novel Triplets to Extend Remission with VENetoclax in Elderly (INTERVENE) Acute Myeloid Leukaemia

Cooperative Group

Australasian Leukaemia and Lymphoma Group (ALLG)

Other Non-Commercial Sponsor

Medical Research Future Fund

Summary

This trial includes a dose finding Run-in phase and a randomised phase. Eligible patients enrolled in the Run-in phase of the trial will received Low dose cytarabine (LDAC) and venetoclax, in combination with either midostaurin OR pracinostat to determine a recommended phase 2 dose. Eligible patients enrolled in the randomised phase of the trial will receive LDAC and venetoclax alone, or in combination with either midostaurin OR pracinostat at the recommended phase 2 dose.

Recruiting Hospitals Read MoreRead more

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Enquiries Line Coordinator
clinicaltrials.enquiries@petermac.org
03 8559 7456 (9am-2pm, Mon-Fri)

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next